Necitumumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Necitumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetEGFR
Clinical data
Trade namesPortrazza
AHFS/Drugs.comMultum Consumer Information
License data
Routes of
administration
Intravenous infusion
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life~14 days
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6436H9958N1702O2020S42
Molar mass144.84 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-small-cell lung carcinoma.[4][5]

References[edit]

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  2. ^ Zosia Chustecka (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28.
  3. ^ [1][dead link]
  4. ^ a b "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). www.accessdata.fda.gov. 2015. Retrieved 2019-09-28.
  5. ^ [2][dead link]